Skip to the news
AgewellGuideGet the weekly briefing

Longevity news · updated October 22, 2026

Longevity news

Dated, sourced updates on longevity clinics, devices and research. Each one explains what changed and whether it should change what you buy, book or skip.

Price card comparing hospital longevity programs: $5,500 at Northwestern, $12,000 at Weill Cornell and up to $45,000 a year

Nonprofit hospitals now sell longevity care, from $5,500 to $45,000 a year

STAT reported on October 6, 2026 that Northwestern Medicine, Weill Cornell and Mayo Clinic have all launched cash-pay longevity clinics, with costs at major hospitals reaching as much as $45,000 a year. Northwestern’s Human Longevity Clinic is part of a $5,500 annual package; Weill Cornell’s own page lists a $12,000 one-year program and a $7,500 baseline assessment, with lab testing billed separately and no insurance coverage. A hospital brand is not the same as evidence: critics quoted by STAT say some programs include tests that lack evidence of improving health. Ask which tests are medically indicated, what is billed on top, and who acts on an abnormal result.

Source · STAT – Longevity clinics are the buzzy new trend at nonprofit hospitals →Northwestern Human Longevity Clinic profile →Mayo Clinic Executive Health profile →What longevity clinics cost →

Oura brings blood-pressure signals and GLP-1 Insights to 30+ more countries

Oura began rolling out Health Radar, including blood-pressure signals, nighttime BP with manual cuff logging and a 30-day nighttime breathing view, plus GLP-1 Insights, to more than 30 new markets on October 6, 2026, including all EU countries, the UK, Canada and Australia. It works on Oura Ring Gen3 and newer. Oura states the features are for general wellness only and do not diagnose, treat or monitor disease. Treat the BP signal as a prompt to check with a validated upper-arm cuff, not as a reading.

Source · Oura – Health Radar and GLP-1 Insights expand to 30+ markets →Validated blood pressure monitors →Oura Ring 5 vs WHOOP 5 →

FDA clears cuffless ring blood pressure, but only for ages 22 to 50

Happy Health announced on October 5, 2026 that the FDA had cleared its Happy Health Blood Pressure Monitor (510(k) K254000, decided September 3), software that derives blood pressure from its Happy Ring without a cuff. The cleared indication is narrow: spot-check systolic and diastolic readings for adults aged 22 to 50, measurement and display only, and not for people with atrial fibrillation or other arrhythmias, on vasoactive drugs, or pregnant. Most longevity buyers are older than the cleared range, so for them a validated upper-arm cuff remains the reference.

Source · FDA 510(k) database – K254000, Happy Health Blood Pressure Monitor →Validated blood pressure monitors →

Prenuvo opens its 200,000-scan MRI biobank to outside researchers

Prenuvo launched the Prenuvo Research Network on September 29, 2026, pairing its imaging biobank of more than 200,000 whole-body MRI scans with researchers from over 50 institutions, including City of Hope, UCSF and Moffitt Cancer Center. The first four studies include incidental brain findings in more than 78,000 people and incidental kidney findings across 117,826 scans. Incidental findings are the core risk question for screening MRI in people without symptoms, so these papers are worth watching, but they are company-led data and do not yet show that scanning healthy people improves outcomes.

Source · AuntMinnie – Prenuvo launches whole-body MRI research network →Prenuvo profile →

Neko Health opens in New York: $499 for a 60-minute scan

Neko Health opened its first U.S. clinic at 300 Lafayette Street in SoHo, New York on September 24, 2026, pricing its 60-minute visit at $499, with HSA and FSA accepted. The visit covers a skin scan from about 6,000 images, a cardiovascular assessment, body composition and on-site blood testing for more than 50 biomarkers, followed by a clinician review; it is radiation-free and is not an MRI. More New York locations and Miami are expected next. Compare it with an MRI-based scan on what each actually measures, not on price alone.

Source · Neko Health press release – Neko Health opens its doors in New York →Neko Health profile →Neko vs Prenuvo vs Ezra vs Human Longevity →

Biolinq Shine cleared OTC: a needle-free glucose sensor that shows ranges, not numbers

Biolinq announced FDA 510(k) clearance on September 24, 2026 for over-the-counter use of Biolinq Shine, a needle-free wearable glucose sensor, for adults 22 and older who do not use insulin. It shows a color-coded light for in, above or below range and is not intended to give numeric glucose values for medical decisions. Price and launch date have not been announced. For a short diet-and-exercise audit, Stelo and Lingo still show actual numbers and can be bought today.

Source · Biolinq press release – Biolinq Shine receives FDA 510(k) clearance →Best OTC CGM: Stelo vs Lingo →

FDA advisers back GRAIL’s Galleri cancer blood test, 7–2, but split 6–4 on effectiveness

An FDA advisory committee voted on September 23, 2026 that the benefits of GRAIL’s Galleri multi-cancer early-detection test outweigh its risks (7 for, 2 against, 1 abstention), with a unanimous vote on safety and a narrower 6–4 vote on effectiveness. The proposed use is adults 50 and older, alongside guideline cancer screening, not instead of it. The test is not yet FDA-approved; a final decision is expected in the coming months. If a clinic or lab sells Galleri, ask what happens after a positive signal and who pays for the follow-up imaging.

Source · GRAIL – FDA advisory committee votes in favor of Galleri →WHOOP Advanced Labs review →

Apple Watch Series 12 adds a Readiness score; no new FDA-cleared feature

Apple announced Apple Watch Series 12 on September 9, 2026 from $399, in stores September 18. It samples heart rate every five seconds, measures HRV up to 24 times more often, and adds a daily 0–10 Readiness score with four recommendations, putting Apple directly against WHOOP and Oura on recovery scoring. Apple’s announcement lists no new FDA-cleared feature. Readiness is a training aid; it does not replace the existing ECG app, sleep apnea notifications or a cuff for blood pressure.

Source · Apple Newsroom – Introducing Apple Watch Series 12 →Trackers and diagnostics →

Semaglutide extended lifespan in old female mice. There is no human longevity data

A Nature paper published September 2, 2026 reports that treating 20-month-old female mice with semaglutide for three months improved physiological function and markers of ageing, and that continued treatment extended lifespan, matching many benefits of calorie restriction. It is a preclinical study in one mouse strain and one sex. It does not show that GLP-1 drugs slow ageing in people and is not a reason to use them off-label for longevity.

Source · Nature – Late-life semaglutide treatment slows ageing and extends lifespan in female mice →

FDA authorizes the first wearable that tracks both ketones and glucose

The FDA authorized Abbott’s Libre Duo on August 25, 2026 through the De Novo pathway: a 10-day sensor that continuously measures both ketones and glucose for people with diabetes aged two and older, with evidence from six clinical studies and more than 600 participants. It is a diabetes safety device built to catch rising ketones before diabetic ketoacidosis, not a wellness CGM. For non-diabetic buyers it changes nothing today, but it shows where consumer sensors may head next.

Source · FDA – FDA authorizes first wearable that continuously monitors ketones and blood sugar →Do non-diabetics need a CGM? →

Which biological-age clocks respond to interventions? A 51-study analysis

A Nature Medicine analysis published August 21, 2026 built TranslAGE, a harmonized database of 51 longitudinal intervention studies, and calculated 16 prominent epigenetic clocks plus 94 other DNA-methylation biomarkers for each. Clocks trained on mortality or pace of ageing, such as GrimAge- and DunedinPACE-type measures, responded most consistently, and results depended heavily on population and study length. Clocks are still not validated surrogate endpoints, so if you buy a biological-age test, ask which clock it uses and do not treat a single result as proof an intervention works.

Source · Nature Medicine – Responsiveness of epigenetic aging biomarkers to longevity interventions in humans →

Simple balance and leg-strength tests predicted survival after 65 in a 13,423-person study

A JAMA Network Open cohort study published August 10, 2026 followed 13,423 Taiwanese adults aged 65 and older (mean age 72.9) for a median of seven years. Compared with the least fit fifth, the fittest fifth had a substantially lower adjusted risk of death on the 8-foot up-and-go (hazard ratio 0.41), one-leg stance (0.50), 30-second chair stand (0.55) and two-minute step test (0.58). It is observational, so it shows association rather than cause, but it supports cheap at-home tests of balance and leg strength alongside VO2 max.

Source · JAMA Network Open – Physical Fitness and All-Cause Mortality in Older Adults →Good VO2 max by age →
Empty clinical consultation room representing the closure of a longevity clinic

Eternal closes its U.S. longevity clinics, citing an unsustainable business model

Eternal, which raised $13 million to deliver DEXA scans, VO2 max testing and physician-led programs across San Francisco and New York, announced July 14 that both clinics would close at the end of the month. CEO Alex Mather said the company could not build a sustainable business despite exploring digital care and AI-coaching pivots. Before joining any longevity clinic, the standard due-diligence question is now worth asking explicitly: what happens to your records, referrals and follow-up protocols if the clinic closes - a physician-staffed, venture-backed operation can fold in under two years.

Source · Fitt Insider – Eternal Shuts Down Its High-Performance Health Platform →

A case report links heat exposure to Alzheimer's resilience - one patient, not a trial

A March 2026 paper in the Journal of Alzheimer's Disease describes a single patient carrying a PSEN2 mutation for early-onset Alzheimer's who maintained cognitive function despite high amyloid burden, with the authors hypothesizing that lifelong occupational heat exposure promoted tau clearance through improved protein homeostasis. The study is a case report of one individual, not a controlled trial, and it establishes a hypothesis, not a treatment. Clearlight infrared saunas issued a press release on July 15 citing the paper and has been selected to supply equipment for a follow-on clinical study, which is the commercial framing to read past. The authors state that the paper does not establish that infrared sauna use prevents or treats Alzheimer's disease.

Source · Canet et al. - Journal of Alzheimer's Disease, March 2026 →

Fountain Life launches a $595/year membership. Ask what it excludes

Independent coverage reported Fountain Life’s new BASE membership at $595 per year, far below its five-figure APEX membership. BASE includes more than 100 blood biomarkers, a DEXA scan, clinician-guided review and digital tracking, but availability and any extra charges still need confirmation. Ask for the current written tier comparison and a complete first-year price before joining.

Source · Longevity.Technology – Fountain Life introduces BASE at $595 →

FDA ends its WHOOP warning: wearable blood-pressure estimates remain wellness data

The FDA closed its warning to WHOOP on June 23, 2026 after the company changed how Blood Pressure Insights is presented. The feature remains a general-wellness estimate, not a medical blood-pressure reading. Use a validated upper-arm cuff for clinical decisions.

Source · MedTech Dive – FDA drops WHOOP warning letter over blood pressure feature →

First wearable cortisol sensor shows in-human proof-of-concept at ADA, not yet cleared

A wearable patch that reads free cortisol from dermal interstitial fluid tracked paired venous blood measurements in a controlled hydrocortisone challenge, Adaptyx Biosciences reported at the American Diabetes Association's 86th Scientific Sessions on June 9, 2026, with more than 400 hours of IRB-approved in-body monitoring as the evidence base. The sensor uses a 16-channel array with cortisol-specific molecular switches to capture the hormone's daily rhythm at minute resolution, which no blood, saliva, or urine test can replicate continuously. Cortisol governs glucose control, cardiovascular stress response, and sleep quality; continuous wearable monitoring could give the longevity-tracking stack a signal that a one-time morning blood draw misses entirely. The device is pre-commercial and pursuing an FDA Class II pathway, not yet cleared; if the regulatory arc resembles the CGM category, commercial availability is at least a few years out.

Source · BusinessWire – Adaptyx Biosciences ADA press release, June 2026 →

Oura Ring 5 costs $399; its blood-pressure signal is not a medical reading

Oura Ring 5 began shipping June 4, 2026 at $399, with a thinner design and a claimed six to nine days of battery life. Its new blood-pressure signal is not an FDA-cleared monitor. Treat it as a trend flag until independent clinical validation is available, and use a validated cuff for actual blood-pressure readings.

Source · BusinessWire – Oura Ring 5 announcement →

FDA extends Stelo OTC CGM to children ages 2 and up: access wider, clinical scope unchanged

On June 12, 2026, the FDA cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter use by people ages two and older who do not use insulin, expanding the original March 2024 adult clearance to pediatric users. The hardware is the same: a 15-day wearable sensor delivering 15-minute glucose readings via smartphone, with adults required as caregivers for child users. The clearance is an access decision, not a shift in evidence: the label excludes insulin-dependent users and does not endorse Stelo as a long-term health monitor for metabolically healthy children. The buyer logic that applied to adults, a short-window audit rather than an open subscription, applies at least as much here.

Source · FDA – Stelo OTC clearance extended to ages 2+ →

OTC CGMs, two years in: the glucose habit still has to earn its keep

Context, not news: the FDA cleared Dexcom Stelo in March 2024 as the first over-the-counter CGM for adults who do not use insulin, including non-diabetics who want diet-and-exercise feedback. Two years on, access is wide but the label is unchanged. It still tells users not to make medical decisions from the output without a clinician, and a useful two-week audit is not the same thing as a forever subscription.

Source · FDA – first OTC CGM clearance →

No smartwatch or ring measures glucose on its own, says FDA

The FDA safety communication is the line to remember: it has not authorized, cleared or approved any smartwatch or smart ring that measures or estimates blood glucose by itself. A watch can display data from a real CGM; it is not the sensor.

Source · FDA – glucose smartwatch warning →

Google launches $99 screenless Fitbit Air into the tracker market

Google released the Fitbit Air on 26 May 2026 at $99.99, a screenless band that delivers HRV monitoring, sleep analysis, and AFib detection at a lower entry price than WHOOP (no device ownership, roughly $199/yr) or Oura (roughly $349 hardware plus $70/yr subscription). No independent accuracy validation has been published for this device yet; the pattern across current wearables is that resting heart rate and HRV read close to clinical reference, while sleep staging barely clears a coin toss against polysomnography. The lower price lowers the stakes for experimentation, not the evidential bar for longevity outcomes.

Source · Google Blog – Introducing Fitbit Air →

The red-light irradiance number you’re sold runs 2–3× high

Independent spectrometer testing keeps landing the same way: the irradiance brands advertise – measured on cheap solar meters – runs two to three times the real figure, and almost no panel clears ~90 mW/cm² at six inches when measured properly. Buy on the measured number, at a stated distance, not the box.

Source · Light Therapy Insiders →

FDA flags hyperbaric chamber fires and off-label aging claims

The FDA’s 2025 guidance to clinicians ties hyperbaric oxygen devices to fires causing serious injuries and deaths, and flags centers promoting unapproved aging and longevity uses. HBOT is not cleared for aging-reversal claims – and the home soft-shell at 1.3 ATA is not the 2.0 ATA dose the longevity studies used.

Source · FDA – Letters to Health Care Providers →

The Agewell Briefing

The longevity news worth your time, once a week.

A sourced weekly read on longevity products, clinics and research, with a clear answer on what is worth trying.

One email a week. Unsubscribe with one click.